Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (
A phase 1/2 trial of Belzutifan, Zanzalintinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) is a phase 1/2 interventional study registered as NCT07049926 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2025-07-20 and due to reach its primary completion in 2031-10-26. Interventions recorded: Belzutifan, Zanzalintinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Shares Zanzalintinib, Merck & Co. (MSD), Renal cell carcinoma.
- TrialA Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Shares Zanzalintinib, Merck & Co. (MSD), Renal cell carcinoma.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TrialA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TrialA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.
- TrialA Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Shares Belzutifan, Renal cell carcinoma.
- TrialBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL
Shares Belzutifan, Merck & Co. (MSD).
- TrialSubstudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma.